Kyverna Therapeutics Files 8-K on Shareholder Votes & Financials
Ticker: KYTX · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1994702
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
Related Tickers: KYTX
TL;DR
KYTX filed an 8-K on 5/29 for shareholder votes & financials.
AI Summary
Kyverna Therapeutics, Inc. filed an 8-K on May 29, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The company, incorporated in Delaware, is involved in biological products, specifically excluding diagnostic substances. The filing details their principal executive offices in Emeryville, California.
Why It Matters
This filing indicates important corporate actions and financial reporting by Kyverna Therapeutics, which could impact investors' understanding of the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate material adverse events.
Key Numbers
- 001-41947 — SEC File Number (Identifies the company's filing history with the SEC.)
- 83-1365441 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- May 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Emeryville, California (location) — Principal Executive Offices
- 5980 Horton St., STE 550 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What is the primary business of Kyverna Therapeutics, Inc.?
Kyverna Therapeutics, Inc. is involved in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' as indicated by its Standard Industrial Classification code [2836].
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated May 29, 2025.
Where are Kyverna Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 5980 Horton St., STE 550, Emeryville, California, 94608.
What is the company's fiscal year end?
The company's fiscal year ends on December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Kyverna Therapeutics, Inc. (KYTX).